1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Australia Pharmaceuticals and Healthcare Report Q3 2016

Australia Pharmaceuticals and Healthcare Report Q3 2016

  • May 2016
  • -
  • Business Monitor International
  • -
  • 101 pages

Includes 3 FREE quarterly updates

BMI View: Drugmakers operating in Australia will face an increasingly challenging business environmentas the Sixth Pharmacy Community Agreement's measures come into effect. This includes a 5% price cut tomedicines listed on the F1 formulary for more than five years, as well as changes to the calculation used inthe price disclosure cycle. Critically, we highlight that biosimilar substitutability and naming will be agrowing area of contention between originator firms and authorities who seek to curtail spending due to theexponential increase in biologics expenditure over the past few years.

Headline Expenditure Projections

- Pharmaceuticals: AUD14.0bn (USD10.5bn) in 2015 to AUD14.5bn (USD9.6bn) in 2016; +3.4% inlocal currency terms and -8.6% in US dollar terms, due to significant exchange rate fluctuations.

- Healthcare: AUD162bn (USD121bn) in 2015 to AUD169bn (USD112bn) in 2016; +4.2% in localcurrency terms and -7.7% in US dollar terms, due to exchange rate fluctuations.

Table Of Contents

Australia Pharmaceuticals and Healthcare Report Q3 2016
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Australia 2012-2020) 14
Healthcare Market Forecast 15
Table: Selected Health Measures In Australia FY2015/16 Budget 16
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Australia 2012-2020) 18
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Australia 2012-2020) 18
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Australia 2012-2020) 19
Prescription Drug Market Forecast 20
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Australia 2012-2020) 22
Patented Drug Market Forecast 23
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Australia 2012-2020) 25
Generic Drug Market Forecast 26
Table: Cost Of Selected Drugs Post-Price Disclosure, April 2013 28
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Australia 2012-2020) 29
OTC Medicines Market Forecast 30
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Australia 2012-2020) 32
Pharmaceutical Trade Forecast 33
Table: Pharmaceutical Trade Data And Forecasts (Australia 2014-2020) 35
Table: Pharmaceutical Trade Data And Forecasts local currency (Australia 2014-2020) 35
Industry Risk Reward Index 36
Asia Pacific Risk/Reward Index - Q3 2016 36
Australia Risk/Reward Index 42
Rewards 42
Risks 43
Regulatory Review 44
Table: EU and ICH Guidelines Adopted In The TGA's Biosimilars Guidance Document 45
Intellectual Property Issues 47
Pricing and Reimbursement Regime 51
Table: Selected Drugs Undergoing SPD (AUD) 52
Table: Historical PBS Co-Payments 53
Table: New PBS Formularies 56
Market Overview 57
Healthcare Sector 57
Research and Development 58
Clinical Trials 59
Epidemiology 60
Table: Estimated Number Of New Cases Of Cancer In Australia 63
Competitive Landscape 65
Research-Based Industry 65
Table: Multinational Market Activity 66
Pharmaceutical Distribution 67
Company Profile 69
Australian Pharmaceutical Industries 69
CSL 72
GlaxoSmithKline 76
Mayne Pharma Group 80
Sanofi 83
Sigma 86
Demographic Forecast 90
Table: Population Headline Indicators (Australia 1990-2025) 91
Table: Key Population Ratios (Australia 1990-2025) 91
Table: Urban/Rural Population and Life Expectancy (Australia 1990-2025) 92
Table: Population By Age Group (Australia 1990-2025) 92
Table: Population By Age Group % (Australia 1990-2025) 93
Glossary 95
Methodology 97
Pharmaceutical Expenditure Forecast Model 97
Healthcare Expenditure Forecast Model 97
Notes On Methodology 98
Risk/Reward Index Methodology 99
Index Overview 100
Table: Pharmaceutical Risk/Reward Index Indicators 100
Indicator Weightings 101

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Frontier Pharma: Breast Cancer - First-in-Class Innovation Clustered Around Growth Factor Signalling Processes

Frontier Pharma: Breast Cancer - First-in-Class Innovation Clustered Around Growth Factor Signalling Processes

  • $ 6 995
  • Industry report
  • February 2016
  • by GBI Research

Frontier Pharma: Breast Cancer - First-in-Class Innovation Clustered Around Growth Factor Signalling Processes Summary The breast cancer pipeline is the largest in the pharmaceutical industry, with 1,050 ...

Opportunity in the Indian Pharmaceutical Market - 2016; Market size, Market share, Market landscape, Market trend analysis, Growth drivers, Future opportunity, Future forecast

Opportunity in the Indian Pharmaceutical Market - 2016; Market size, Market share, Market landscape, Market trend analysis, Growth drivers, Future opportunity, Future forecast

  • $ 5 750
  • Industry report
  • April 2016
  • by Feedback Business Consulting

This report provides an insight into the Indian Pharmaceutical current market scenario, structure and practices. In depth market scenario includes; - Current market size estimates, including domestic market, ...

Omega 3 PUFA Market: Type (DHA (docosahexaenoic acid), EPA (eicosapentaenoic acid), ALA (Alpha-linoleic acid)) Source (Marine, Plant) Form (Oils, Capsules, Powder) Application (Dietary Supplements, Pharmaceuticals, Infant Foods, F&B)-Forecast(2015-2020)

Omega 3 PUFA Market: Type (DHA (docosahexaenoic acid), EPA (eicosapentaenoic acid), ALA (Alpha-linoleic acid)) Source (Marine, Plant) Form (Oils, Capsules, Powder) Application (Dietary Supplements, Pharmaceuticals, Infant Foods, F&B)-Forecast(2015-2020)

  • $ 5 250
  • Industry report
  • February 2016
  • by Industry ARC

Omega-3 fatty acids are polyunsaturated fatty acids which have potential health benefits and are essential for increasing metabolic rate. Omega-3 PUFA ingredients are used to manufacture products that ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.